Jatt II Acquisition Corp. 预计,在交易完成时,合并后公司拥有的可用现金将足以支持其候选药物Tala-125的研发进程,直至2028年下半年获得IIb期临床试验的关键数据读出。
Jatt II Acquisition Corp. 预计,在交易完成时,合并后公司拥有的可用现金将足以支持其候选药物Tala-125的研发进程,直至2028年下半年获得IIb期临床试验的关键数据读出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.